Design Therapeutics (DSGN) Competitors $5.33 +0.17 (+3.29%) Closing price 04:00 PM EasternExtended Trading$5.32 -0.01 (-0.17%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. LENZ, MLYS, ZYME, NRIX, TRVI, XERS, ORIC, UPB, DNA, and PHARShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include LENZ Therapeutics (LENZ), Mineralys Therapeutics (MLYS), Zymeworks (ZYME), Nurix Therapeutics (NRIX), Trevi Therapeutics (TRVI), Xeris Biopharma (XERS), Oric Pharmaceuticals (ORIC), Upstream Bio (UPB), Ginkgo Bioworks (DNA), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors LENZ Therapeutics Mineralys Therapeutics Zymeworks Nurix Therapeutics Trevi Therapeutics Xeris Biopharma Oric Pharmaceuticals Upstream Bio Ginkgo Bioworks Pharming Group Design Therapeutics (NASDAQ:DSGN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of DSGN or LENZ? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 23.5% of Design Therapeutics shares are owned by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, DSGN or LENZ? Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Which has stronger valuation and earnings, DSGN or LENZ? LENZ Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$1.12-4.76LENZ TherapeuticsN/AN/A-$49.77M-$1.90-19.92 Does the media prefer DSGN or LENZ? In the previous week, LENZ Therapeutics had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for LENZ Therapeutics and 3 mentions for Design Therapeutics. LENZ Therapeutics' average media sentiment score of 0.62 beat Design Therapeutics' score of 0.35 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENZ Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DSGN or LENZ more profitable? LENZ Therapeutics' return on equity of -25.63% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -27.15% -26.07% LENZ Therapeutics N/A -25.63%-24.43% Do analysts recommend DSGN or LENZ? LENZ Therapeutics has a consensus target price of $49.60, suggesting a potential upside of 31.04%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryLENZ Therapeutics beats Design Therapeutics on 8 of the 14 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.85M$3.11B$5.63B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-4.767.0921.9023.75Price / SalesN/A367.51465.67116.64Price / CashN/A42.3037.4059.05Price / Book1.438.659.096.18Net Income-$49.59M-$54.65M$3.25B$264.89M7 Day Performance24.53%6.59%4.76%2.66%1 Month Performance35.97%9.57%6.72%3.05%1 Year Performance24.24%14.06%30.51%25.05% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.2815 of 5 stars$5.33+3.3%N/A+22.3%$293.85MN/A-4.7640News CoverageAnalyst RevisionLENZLENZ Therapeutics1.863 of 5 stars$30.92+5.4%$49.60+60.4%+74.1%$880.33M$5M-16.24110MLYSMineralys Therapeutics3.3579 of 5 stars$13.48+3.5%$32.25+139.2%+54.8%$879.87MN/A-3.6228News CoverageEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionZYMEZymeworks0.1217 of 5 stars$12.61+0.1%N/AN/A$878.67M$76.30M-8.46460NRIXNurix Therapeutics2.5812 of 5 stars$11.47+1.6%$28.87+151.8%-51.8%$871.76M$54.55M-4.37300TRVITrevi Therapeutics3.0753 of 5 stars$7.43-0.8%$20.88+181.0%+187.0%$866.19MN/A-16.4120XERSXeris Biopharma3.421 of 5 stars$5.50-1.2%$6.25+13.7%+186.3%$854.46M$203.07M-18.21290News CoverageAnalyst UpgradeInsider TradeAnalyst RevisionORICOric Pharmaceuticals4.7264 of 5 stars$10.05+3.0%$18.57+84.9%+0.6%$851.77MN/A-5.3480News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↓Analyst RevisionUPBUpstream Bio1.8735 of 5 stars$15.89+1.8%$56.50+255.6%N/A$848.87M$2.30M0.0038DNAGinkgo Bioworks0.9784 of 5 stars$14.45+6.3%$8.50-41.2%N/A$846.52M$227.04M-1.58640PHARPharming Group2.1197 of 5 stars$12.15-0.9%$30.00+147.0%+45.7%$832.05M$297.20M-93.42280Short Interest ↑Gap Up Related Companies and Tools Related Companies LENZ Alternatives MLYS Alternatives ZYME Alternatives NRIX Alternatives TRVI Alternatives XERS Alternatives ORIC Alternatives UPB Alternatives DNA Alternatives PHAR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access